Multivalent Supramolecular Nanosystems as Dynamic Virus Blockers
SupraVir aims to develop self-adaptive supramolecular assemblies that mimic host cell receptors to create universal virus blockers effective against diverse and rapidly mutating viruses.
Projectdetails
Background
Viral pandemics pose great risks to current and future human health and global trade. Newly emerging viruses can display a broad variety of shapes, such as spherical or filamentous, and spike proteins have different lengths and densities, as seen in coronaviruses and influenza viruses.
Viruses can mutate rapidly under evolutionary pressure, resulting in changes to antigen epitopes and reduced efficacy of drugs and vaccines. These variances between viruses and across mutations present challenges to broad-based anti-infection intervention and vaccination. However, the initial docking of viruses to cell surface receptors via heparan sulfate or polysialic acids are common for a number of viruses, offering an attractive target for wide-reaching intervention.
Aim
The SupraVir project will provide a new concept for multivalent supramolecular assemblies as self-adaptive universal virus blockers. This new type of virus inhibitor can adapt to different virus morphologies and mutations by dynamic self-assembly of its virus binding sites.
The inhibitor will use a combination of different receptors and bind a great majority of all known viruses by mimicking generic host cell surface receptors.
Methodology
My approach will use self-assembled surface-active supramolecules that mimic the host cell surface efficiently and dynamically. With this method, I will avoid a bulk phase that does not contribute to the activity, thus reducing potential toxicity.
At the same time, the amphiphilic building blocks can interfere with the viral envelope or capsid and permanently inactivate the virus.
Impact
SupraVir addresses the central question: What might prevention of viral infections look like in 2030? I contend that there is a new option, based on mimicking dynamic cell surface receptors with multivalent supramolecular nanosystems that can self-adapt to inactivate rapidly mutating viruses.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.849.138 |
Totale projectbegroting | € 2.849.138 |
Tijdlijn
Startdatum | 1-10-2022 |
Einddatum | 30-9-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- FREIE UNIVERSITAET BERLINpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Molecular dissection of viral genomes for future antiviral treatmentsThis project aims to identify and characterize virus-encoded transmembrane proteins as novel pharmaceutical targets for antiviral drug discovery and treatment of viral infections. | ERC Advanced... | € 2.420.301 | 2023 | Details |
Structure and Function-based Design of Vaccine Antigens and Antiviral ImmunotherapiesThis project aims to revolutionize vaccine antigen design by utilizing nanobody screening and deep learning to extract insights from viral glycoproteins, enhancing efficacy against high-risk viruses. | ERC Starting... | € 1.499.525 | 2025 | Details |
Deciphering the nanobiophysics of virus-host interactions in 3D cellular systemsThis project aims to elucidate virus-host interactions during entry in 3D environments using advanced nanotechniques, potentially leading to new antiviral drug discoveries. | ERC Consolid... | € 2.867.346 | 2023 | Details |
Virus Inhibition by siRNA Optimized by NMRThis project aims to develop a novel class of siRNA molecules targeting SARS-CoV-2 variants using structural biology, with potential applications for other pathogenic viruses. | ERC Proof of... | € 150.000 | 2022 | Details |
Hit-to-Lead Development of potent broad-spectrum coronavirus fusion inhibitorsThis project aims to develop and optimize broad-spectrum antiviral drugs targeting the S2 domain of coronaviruses to prevent future outbreaks and enhance antiviral therapy markets. | ERC Proof of... | € 150.000 | 2022 | Details |
Molecular dissection of viral genomes for future antiviral treatments
This project aims to identify and characterize virus-encoded transmembrane proteins as novel pharmaceutical targets for antiviral drug discovery and treatment of viral infections.
Structure and Function-based Design of Vaccine Antigens and Antiviral Immunotherapies
This project aims to revolutionize vaccine antigen design by utilizing nanobody screening and deep learning to extract insights from viral glycoproteins, enhancing efficacy against high-risk viruses.
Deciphering the nanobiophysics of virus-host interactions in 3D cellular systems
This project aims to elucidate virus-host interactions during entry in 3D environments using advanced nanotechniques, potentially leading to new antiviral drug discoveries.
Virus Inhibition by siRNA Optimized by NMR
This project aims to develop a novel class of siRNA molecules targeting SARS-CoV-2 variants using structural biology, with potential applications for other pathogenic viruses.
Hit-to-Lead Development of potent broad-spectrum coronavirus fusion inhibitors
This project aims to develop and optimize broad-spectrum antiviral drugs targeting the S2 domain of coronaviruses to prevent future outbreaks and enhance antiviral therapy markets.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Fighting Large-Scale Untreated Infectious Diseases with Innovative TreatmentsMeletios is developing a broad-spectrum oral antiviral that targets cell mechanisms to treat acute viral infections, starting with COVID-19, while also managing immune responses. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Fighting Large-Scale Untreated Infectious Diseases with Innovative Treatments
Meletios is developing a broad-spectrum oral antiviral that targets cell mechanisms to treat acute viral infections, starting with COVID-19, while also managing immune responses.